Corridor
Consult
What To Do for the Patient with Minimally Elevated Creatinine Level?|
pdf
>>
By
Antoine C Abcar, MD; Larry Chan, MD; Hock Yeoh, MD
Introduction
Clinicians
must often decide what do to for an asymptomatic patient who has minimally
elevated serum creatinine level. Serum creatinine concentration is used
clinically as a convenient index of kidney function, but it is important
to remember that even a minimal elevation in creatinine can reflect
significantly decreased rate of glomerular filtration. In fact, up to
40% of patients with normal serum creatinine level may have some reduction
in glomerular filtration rate.1 Calculation of the glomerular
filtration rate is very important to more accurately measure and assess
kidney function. We present a typical clinical situation and suggest
a possible course of evaluation and treatment.
Case Example
You are
evaluating a 55-year-old white woman who has a 14-year history of diabetes
mellitus and a 20-year history of hypertension and who previously received
treatment for diabetic retinopathy. The patient's blood pressure measured
in the office is 142/88 mm Hg, weight is 156 lb (70.2 kg), most recent
blood glycosylated hemoglobin (HBA1C) measurement was 8.2%
of total hemoglobin, and most recent low-density lipoprotein (LDL) cholesterol
level was 145 mg/dL (3.75 mmol/L). The patient's current regimen for
blood pressure control includes hydrochlorothiazide, 25 mg per day;
atenolol, 25 mg per day and clonidine, 0.1 mg twice a day; and for blood
glucose control she uses glipizide at 5 mg per day. The patient has
no known history of heart disease or congestive heart failure. Result
of a serum creatinine test obtained just before this visit is 1.3 mg/dL
(114.92 mol/L), which is the same result as that obtained three months
earlier. The reference ranges for serum creatinine are 0.7 to 1.3 mg/dL
(61.9-114.9 mol/L) in men and 0.6 to 1.1 mg/dL (53.0-97.2 mol/L) in
women.
Assessing Renal Function
Because
the serum creatinine value is elevated slightly, results of her previous
serum creatinine tests should be reviewed, and the test should be repeated
if this is the first elevated value noted. The next step is to stage
the patient's renal disease according to recent Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines.1 Glomerular filtration
rate (expressed as mL/min/1.73 m2 of body surface area) can
be estimated using the Modification of Diet in Renal Disease (MDRD)
formula: 186 (serum creatinine in mg/dL)1.154 (age in years)0.203
(0.742 if female) (1.212 if African American).2 Soon, Kaiser
Permanente Southern California clinical laboratories will calculate
and report estimated glomerular filtration rate by using this formula.
An online glomerular filtration rate calculator that uses this formula
can be accessed at the Kidney Disease Outcome Quality Initiative (KDOQI)
Web site: www.kidney.org/professionals/kdoqi/index.cfm. Historically,
24-hour urine collection was used to assess creatinine clearance. However,
this method is time-consuming and frequently inaccurate because of improper
specimen collection. For example, undercollection leads to falsely low
estimates of glomerular filtration rate. Accuracy of the MDRD formula
is validated, and use of this formula is currently the preferred method
for estimating glomerular filtration rate.
Application
of the MDRD formula to the data for this patient yields a glomerular
filtration rate of 46 mL/min/1.73 m2. According to the most
recent guidelines, calculated glomerular filtration rate can be used
to classify chronic kidney disease into five stages (Table 1);1
the chronic kidney disease in the case example is at stage three. Despite
minimal elevation in serum creatinine level, the patient has moderate
reduction in glomerular filtration rate. Reduced glomerular filtration
rate warrants investigation of potential causative or contributive factors,
including chronic medical conditions, prescription or over-the-counter
medication, and urinary tract obstruction. The chronic conditions most
commonly associated with decreased glomerular filtration rate are hypertension
or diabetes. Medication use should be carefully reviewed, particularly
use of nonsteroidal anti-inflammatory or other nephrotoxic medications,
and less-nephrotoxic agents should be substituted when possible. The
patient's medical and family history, physical examination findings,
and symptoms (if any) should be evaluated for evidence suggestive of
obstructive nephropathy.
The next
diagnostic procedure is urinalysis to screen for hematuria and proteinuria.
The K/DOQI guidelines accept use of a standard urine dipstick to screen
for proteinuria:1 Proteinuria of 1+ or higher requires further
quantification and confirmation.
The K/DOQI
guidelines recommend using an untimed ("spot") urine sample
to determine the albumin-to-creatinine ratio instead of using the traditional
timed (eg, 24-hour) urine collection method.1 Results of
urinalysis from a spot sample can be used to accurately estimate daily
urinary albumin loss. A first-morning-urine specimen is optimal, but
a random urine specimen is also acceptable. If the magnitude of proteinuria
is within the nephrotic range (ie, >3 g/d), referral of the patient
to the nephrology department should be considered. If the patient has
subnephrotic-range proteinuria (ie, <3 g/d), angiotensin converting
enzyme (ACE) inhibitors (such as lisinopril) or angiotensin II receptor
blockers (such as losartan) should be prescribed unless contraindicated,
and the dosage should be adjusted according to the patient's blood pressure
response. Serum potassium and creatinine levels should be checked about
7-10 days after the patient begins taking any of these medications;
up to 30% increase in serum creatinine level is often seen within this
time period and is not an indication to discontinue medication use.
These medications will reduce proteinuria while providing a renal protective
effect and are especially important in patients with diabetic nephropathy.
If the patient is unable to take these medications, a nondihydropyridine
calcium channel blocker such as diltiazem or verapamil should be prescribed.
These medications reduce proteinuria but are considered second-line
agents.
 |
| Adapted
and reproduced by permission of the publisher and author from: National
Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative
(K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification.
Am J Kidney Dis 2002 Feb;39(2 Suppl 1):S1-246.1 |
For this
case example, results of urinalysis show proteinuria (1+) without hematuria,
white blood cells, or casts. Follow-up urinalysis of a spot sample show
an albumin-creatinine ratio consistent with urine protein loss of 1.2
grams per day.
Slowing Progression of
Renal Disease
For patients
with decreased kidney function, measures to reduce or retard the progression
of renal disease such as control of hypertension, hypercholesterolemia,
and hyperglycemia should be emphasized. The target blood pressure for
any patient with chronic kidney disease should be 130/80 mm Hg;3
for patients with urine protein loss of more than 1 gram per day, the
target blood pressure should be 125/75 mm Hg.4 The target
LDL cholesterol level should be 100 mg/dL (2.6 mmol/L),5
and the target HBA1C should be 7% of total hemoglobin.5
This patient
began taking lisinopril at a dosage of 10 mg per day, and the dosage
was adjusted to achieve her target blood pressure. The proteinuria was
requantified three months later, and urine protein loss had decreased
to 0.3 grams per day. The patient was counseled on the importance of
blood glucose control, and the glipizide dosage was adjusted to achieve
the target glycosylated hemoglobin value. She eventually began taking
lovastatin and made dietary and lifestyle modifications to reach the
target LDL cholesterol level.
Summary
As this
case demonstrates, even a slightly elevated serum creatinine level can
indicate presence of clinically significant kidney disease. Therefore,
calculated glomerular filtration rate, instead of absolute serum creatinine
level, should be used to evaluate kidney function. If nephrotic-range
proteinuria is present or if the patient has other indications of renal
disease, such as red blood cells or casts in the urine sediment, referral
to a nephrologist should be considered. Patients with
any
degree of chronic kidney disease should have their blood pressure, blood
glucose level, and blood cholesterol level managed aggressively to help
reduce or prevent the progression of kidney disease as well as to reduce
risk of cardiovascular events.
Acknowledgments
Woldemariam
Gebreselassie, MD, and Mohammed Idroos, MD, reviewed the manuscript.
References
- National
Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative
(K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic
kidney disease: evaluation, classification, and stratification. Am
J Kidney Dis 2002 Feb:39(2 Suppl 1):S1-246.
- Levey
AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate
method to estimate glomerular filtration rate from serum creatinine:
a new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999 Mar 16;130(6):461-70.
- Chobanian
AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure; National High Blood Pressure Education
Program Coordinating Committee. The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure: the JNC 7 report [published erratum appears in JAMA
2003 Jul 9;290(2):197]. JAMA 2003 May 21:289(19):2560-72. Epub 2003
May 14.
- Peterson
JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria,
and the progression of renal disease. The Modification of Diet in
Renal Disease Study. Ann Intern Med 1995 Nov 15;123(10):754-62.
- Kaiser
Permanente Southern California. Clinical practice guidelines: chronic
kidney disease (CKD). Available from: http://wpsapp15.crdc.kp.org/pkc/scal/cpg/cpg/html/CKD.html
(accessed December 11, 2003).
To
Clinical Contributions contents list >>
To
full contents list >>